SpainTuberculosis profile
Population  2016 46 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.28 (0.28–0.29) 0.61 (0.61–0.62)
Mortality (HIV+TB only) 0.053 (0.035–0.075) 0.11 (0.07–0.16)
Incidence  (includes HIV+TB) 4.7 (4–5.5) 10 (8.7–12)
Incidence (HIV+TB only) 0.34 (0.29–0.41) 0.74 (0.62–0.88)
Incidence (MDR/RR-TB)** 0.23 (0.16–0.3) 0.5 (0.33–0.66)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.2 (0.17–0.23) 1.6 (1.4–1.9) 1.8 (1.6–2.1)
Males 0.22 (0.19–0.25) 2.7 (2.3–3.1) 2.9 (2.4–3.3)
Total 0.42 (0.35–0.48) 4.3 (3.7–5) 4.7 (4–5.5)
TB case notifications, 2016  
Total cases notified 4 877
Total new and relapse 4 734
          - % tested with rapid diagnostics at time of diagnosis 20%
          - % with known HIV status  
          - % pulmonary 72%
          - % bacteriologically confirmed among pulmonary 86%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 100% (87–120)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.07 (0.06–0.08)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  170
(120–220)
Estimated % of TB cases with MDR/RR-TB 4.2% (2.9–5.8) 18% (9.4–30)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: , XDR-TB:
Patients started on treatment **** MDR/RR-TB: , XDR-TB:
Treatment success rate and cohort size Success Cohort
New cases registered in 2015    
Previously treated cases registered in 2015    
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014    
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-18 Data: www.who.int/tb/data